Akebia receives FDA approval for anemia drug Vafseo
Akebia Therapeutics Inc. has received FDA approval for its oral anemia drug Vafseo for treating anemia in adults with end-stage kidney disease on dialysis for at least 3 months.“With the approval of Vafseo in the U.S., we’re proud to deliver an alternative treatment option for the hundreds of thousands of Americans on dialysis who are diagnosed with anemia due to [chronic kidney